Background
==========

The presentation of FMF is extremely variable, ranging from a quiescent to severe disabling disease. The M694V mutation is one of approximately 300 published genetic variations of MEFV and is thought to be associated with a typical clinical picture of the disease, but studies featuring the phenotype of homozygous M694V phenotype are meager.

Objectives
==========

To describe the clinical trait of M694V homozygous FMF as compared to the phenotype of FMF with mixed MEFV genotypes.

Patients and methods
====================

Fifty seven FMF patients homozygous for the M694V genotype were compared to 56 patients carrying other mutations. A questionnaire, including items related to demographic and clinical features was completed for each patient based on interview, physical examination and file notes.

Results
=======

Compared with the control group, more patients, homozygous for the M694 mutation, suffered from a severe disease (p=0.001), had higher frequency of attacks before and during colchicine treatment (p=0.0001 and 0.0007, respectively), had more related diseases (p=0.0373) and needed higher dose of colchicine to control their disease (p=0.0001). Most other features tested (Table [1](#T1){ref-type="table"}) appeared to be more pronounced in M694V homozygous patients (either with or without statistical significance).

Conclusion
==========

The phenotype of FMF, as manifested in M694V homozygous patients, is the gold standard, to which other FMF presentations should be compared.

  Parameter                                   694 Homozygous (N=57)   Other mutations (N=56)   P
  ------------------------------------------- ----------------------- ------------------------ --------------
  Average length of attack (days)             2.66±1.5                3.03±1.2                 0.073
                                                                                               
  Abdominal attacks                           50 (87.7%)              48 (85.7%)               0.788
                                                                                               
  Arthritis attacks                           52 (91.3%)              28 (50%)                 **\<0.0001**
                                                                                               
  Pleuritis attacks                           36 (46.2%)              18 (38.2%)               **0.0013**
                                                                                               
  Exertional leg-pain                         47 (82.5%)              36 (64.3%)               **0.034**
                                                                                               
  ELE attacks                                 10 (17.5%)              3 (5.4%)                 0.073
                                                                                               
  Attacks of fever alone                      20 (35.1%)              12 (21.4%)               0.143
                                                                                               
  Average colchicine dose (mg/day)            1.9±0.48                1.48±0.54                **0.0001**
                                                                                               
  IV colchicine treatment                     5 (8.8%)                0 (0%)                   0.057
                                                                                               
  Proteinuria or amyloidosis                  6 (10.5%)               1 (1.8%)                 0.113
                                                                                               
  Anemia of chronic disease                   14/53 (26.4%)           7/52 (13.5%)             0.142
                                                                                               
  Elevated acute phase reactants              10/18 (55.6%)           4/16 (25%)               0.092
                                                                                               
  Chronic renal failure                       6 (10.5%)               0 (0%)                   **0.027**
                                                                                               
  Chronic arthritis                           11 (19.3%)              2 (3.6%)                 **0.015**
                                                                                               
  Work days lost each month                   4.4±7.2                 2.6±4.6                  0.718
                                                                                               
  Harm to quality of life                     (1-10) 5.6±3.3          4.1±3                    **0.013**
                                                                                               
  Number of attacks per year w colchicine     7.2±7.8                 3.5±5.5                  **0.0007**
                                                                                               
  Number of attacks per year w/o colchicine   23.6±9.3                15.6±11.7                **0.0001**
                                                                                               
  Crohn\'s disease                            4 (7%)                  2 (3.6%)                 0.679
                                                                                               
  Ankylosing Spondylitis                      3 (5.3%)                1 (1.8%)                 0.619
                                                                                               
  Behcet\'s Disease                           7 (12.3%)               1 (1.8%)                 0.061
                                                                                               
  Henoch Schonlein Purpura                    1 (1.8%)                0                        1
                                                                                               
  All FMF associated diseases                 17 (29.8%)              7 (12.5%)                **0.0373**
